791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

J.M Versluis,R Elens,I.L.M Reijers,A.M Menzies,A.A.M Van Der Veldt,E Kapiteijn,E.A Rozeman,M.C Klop,W Van Houdt,R.P.M Saw,C.L Zuur,T.E Pennington,B Van De Wiel,R.A Scolyer,A Broeks,A.C.J Van Akkooi,G.V Long,C.U Blank

doi:10.1016/j.annonc.2022.07.917

791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

J.M Versluis, R Elens + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.917

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Leiden University Medical Center, Melanoma Institute Australia, Erasmus MC

#Nivolumab In Stage #Neoadjuvant Ipilimumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pathologic (path) response (resp) is an excellent surrogate marker for long-term recurrence-free survival after neoadjuvant (neoadj) IPI + NIVO in stage III melanoma. Few resp pts develop recurrence of disease, and their clinical characteristics and mechanisms of tumor immune escape are unknown.

Full Text